Stem Cell Transplantation in Cardiovascular Disease: An Update

Teng, Miao; Geng, Zhe; Huang, Lan; Zhao, Xinshu

doi:10.1177/147323001204000301

Cited by 2 publications

(1 citation statement)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These issues with autologous stem cell harvesting have raised the question of allogenic sources of stem cell. However in order for this to be feasible allogeneic stem cell must lack both, major histocompatibility complex antigens and various costimulatory cell surface antigens and more trials to be performed with allogeneic stem cells for further evaluation of their safety and feasibility [54]. Long-term immune suppression is undesirable, as it poses extreme risks for infection, development of malignancies, and patient well-being.…”

Section: Which Stem Cell?mentioning

confidence: 99%

Critical appraisal of stem cell therapy in peripheral arterial disease: Do current scientific breakthroughs offer true promise or false hope?

Sultan¹,

Hynes²

2014

JBiSE

View full text Add to dashboard Cite

Over the last forty years in the field of peripheral arterial disease, there has been a plethora of research into cell-based therapies for tissue repair, regeneration and angiogenesis, progressing from protein-based therapies to gene therapies to stem cell research. Initial pre-clinical research successes have given birth to a whole industry, aimed at translating these laboratory hopes into clinical successes. However, heretofore these expected clinical results have failed to materialize, in part due to the lack of attention to the ischaemic desert like tissue and systemically diseased patient into which the stem cells are being implanted. Unsatisfactory clinical outcomes on the treatment of Critical Limb Ischaemia (CLI) have forced researchers to direct their efforts to the less intimidating challenge of claudication and to lower their clinical outcome thresholds from superior to "non-inferior". Major questions on safety and durability have also arisen. What needs to be objectively established is the impact on the net health outcome of these therapies. Infusion or injection for stem cell therapy is still considered experimental and investigational. In this review we examine the clinical evidence for angiogenic therapies, focusing specifically on stem cell trials, in an attempt to answer the question "Is stem cell therapy a failed experiment or will there be light at the end of the tunnel?"

show abstract

Section: Which Stem Cell?mentioning

confidence: 99%